The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1, first-in-human study of DS-2243, an HLA-A*02/NY-ESO–directed bispecific T-cell engager, in patients with advanced solid tumors.
 
Sandra D'Angelo
Honoraria - AADi; Adaptimmune; GI Innovation; GlaxoSmithKline; Incyte; Nektar; Pfizer; Rain Therapeutics; SERVIER
Consulting or Advisory Role - AADi; Adaptimmune; GI Innovation; GlaxoSmithKline; Medendi; Nektar; Pfizer; Rain Therapeutics; Ratio therapeutics; Replimune; Servier
Research Funding - Amgen; Bristol-Myers Squibb.; Deciphera; EMD Serono; Incyte; Merck; Nektar
Travel, Accommodations, Expenses - Adaptimmune; EMD Serono; Nektar
Other Relationship - Adaptimmune; GlaxoSmithKline; Merck; Nektar
 
Vivek Subbiah
Consulting or Advisory Role - AADi; Abbvie (Inst); Bayer (Inst); Foundation Medicine; Illumina; Incyte (Inst); Loxo/Lilly; Novartis (Inst); Pfizer (Inst); Pheon Therapeutics (Inst); Relay Therapeutics (Inst); Roche (Inst)
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Relay Therapeutics (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Other Relationship - Clinical Care Options; Medscape
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bayer; BMS; Deciphera; Ignyta; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; Karyopharm Therapeutics; Pharmamar; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); DEciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); OSE Pharma (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Michael Wagner
Consulting or Advisory Role - AADi; Boehringer Ingelheim; Deciphera; Pharmaessentia; SpringWorks Therapeutics
Research Funding - Adaptimmune (Inst); Deciphera (Inst); Foghorn Therapeutics (Inst); Incyte (Inst); Presage Biosciences (Inst)
Travel, Accommodations, Expenses - Cogent Biosciences; Cogent Biosciences
 
Neeltje Steeghs
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Celgene; Ellipses Pharma (Inst); GlaxoSmithKline; GlaxoSmithKline (Inst); Incyte; Incyte (Inst)
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CellCentric (Inst); Cogent Biosciences (Inst); Crescendo Biologics (Inst); Daiichi Sankyo/Lilly (Inst); Daiichi Sankyo/Lilly (Inst); Deciphera (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Iambic (Inst); IDRx (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Kling Biotherapeutics (Inst); Lixte Biotechnology (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Molecular Partners (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche (Inst); Sanofi (Inst); Zentalis (Inst)
 
Jeonghwan Youk
Honoraria - Astellas Pharma; AstraZeneca; Boryung Pharmaceuticals; Celltrion; Merck; Novartis; Novartis; Yuhan
Consulting or Advisory Role - Boryung Pharmaceuticals; Daiichi Sankyo/Astra Zeneca
Research Funding - Alkermes; Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca (Inst); Eisai; Genentech; Gilead Sciences; Immunomedics; Incyte; Iovance Biotherapeutics; Lilly; Merck; Pfizer; Roche; Scholar Rock; Selexine
Travel, Accommodations, Expenses - Roche/Genentech
 
Hideki Mizusako
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Chugai Pharma; Daiichi Sankyo
 
Yoshihiro Ohue
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Jin Jin
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Abdul Waheed Rajper
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
Research Funding - Daiichi Sankyo
 
Nicole Tesar
Employment - Bioage; Daiichi Sankyo US
Stock and Other Ownership Interests - Bioage
Travel, Accommodations, Expenses - Bioage; Daiichi Sankyo US
 
Patrick Schöffski
Consulting or Advisory Role - Adcendo; Boehringer Ingelheim; Boxer Capital; Cogent Biosciences; Deciphera; Ellipses Pharma; Exelixis; Guidepoint Global; IDRx; LLX Solutions; Medpace; Merck; NEC OncoImmunity AS; Oncode accelerator; SERVIER; Studiecentrum voor Kernenergie (SCK CEN); Telix Pharmaceuticals; Thermosome; Transgene; UCB
Research Funding - Adcendo (Inst); Eisai (Inst); G1 Therapeutics (Inst); Merck (Inst); ONA therapeutics (Inst); PharmaMar (Inst); Sartar Therapeutics (Inst)